Vanguard Asset Management
CYTK icon

Vanguard Asset Management’s Cytokinetics CYTK Stock Holding History

Vanguard Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.62M Buy
112,918
+5,924
+6% +$425K 0.01% 739
2026
Q1 		$7.05M Buy
+106,994
New +$6.8M 0.01% 781

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's CYTK Position: Q2 2026 in Review

Vanguard Asset Management increased its Cytokinetics (CYTK) stake by 5.5% in Q2 2026, buying an estimated $425K and bringing the position to 112,918 shares worth $9.62M. The position accounts for 0.01% of the portfolio, ranked #739.

Vanguard Asset Management first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Asset Management held 112,918 shares of Cytokinetics worth $9.62M as of Q2 2026.
  • Vanguard Asset Management bought 5,924 Cytokinetics shares in Q2 2026, an estimated $425K.
  • Cytokinetics made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #739 holding.
  • Vanguard Asset Management first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 475 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.